Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 34

Cited In for PubMed (Select 12764051)

1.

Presynaptic Mechanisms of l-DOPA-Induced Dyskinesia: The Findings, the Debate, and the Therapeutic Implications.

Cenci MA.

Front Neurol. 2014 Dec 15;5:242. doi: 10.3389/fneur.2014.00242. eCollection 2014. Review.

2.

The relationship between obsessive-compulsive symptoms and PARKIN genotype: The CORE-PD study.

Sharp ME, Caccappolo E, Mejia-Santana H, Tang MX, Rosado L, Orbe Reilly M, Ruiz D, Louis ED, Comella C, Nance M, Bressman S, Scott WK, Tanner C, Waters C, Fahn S, Cote L, Ford B, Rezak M, Novak K, Friedman JH, Pfeiffer R, Payami H, Molho E, Factor SA, Nutt J, Serrano C, Arroyo M, Pauciulo MW, Nichols WC, Clark LN, Alcalay RN, Marder KS.

Mov Disord. 2015 Feb;30(2):278-83. doi: 10.1002/mds.26065. Epub 2014 Nov 12.

PMID:
25393808
3.

PARK2 patient neuroprogenitors show increased mitochondrial sensitivity to copper.

Aboud AA, Tidball AM, Kumar KK, Neely MD, Han B, Ess KC, Hong CC, Erikson KM, Hedera P, Bowman AB.

Neurobiol Dis. 2014 Oct 12;73C:204-212. doi: 10.1016/j.nbd.2014.10.002. [Epub ahead of print]

PMID:
25315681
4.

Parkin (PARK 2) mutations are rare in Czech patients with early-onset Parkinson's disease.

Fiala O, Zahorakova D, Pospisilova L, Kucerova J, Matejckova M, Martasek P, Roth J, Ruzicka E.

PLoS One. 2014 Sep 19;9(9):e107585. doi: 10.1371/journal.pone.0107585. eCollection 2014.

5.

Cerebellum in levodopa-induced dyskinesias: the unusual suspect in the motor network.

Kishore A, Popa T.

Front Neurol. 2014 Aug 18;5:157. doi: 10.3389/fneur.2014.00157. eCollection 2014. Review.

6.

Genetic diagnosis of two dopa-responsive dystonia families by exome sequencing.

Sun ZF, Zhang YH, Guo JF, Sun QY, Mei JP, Zhou HL, Guan LP, Tian JY, Hu ZM, Li JD, Xia K, Yan XX, Tang BS.

PLoS One. 2014 Sep 2;9(9):e106388. doi: 10.1371/journal.pone.0106388. eCollection 2014.

7.

Ubiquitin pathways in neurodegenerative disease.

Atkin G, Paulson H.

Front Mol Neurosci. 2014 Jul 8;7:63. doi: 10.3389/fnmol.2014.00063. eCollection 2014. Review.

8.

HSPA1A-independent suppression of PARK2 C289G protein aggregation by human small heat shock proteins.

Minoia M, Grit C, Kampinga HH.

Mol Cell Biol. 2014 Oct 1;34(19):3570-8. doi: 10.1128/MCB.00698-14. Epub 2014 Jul 14.

9.

Parkin is activated by PINK1-dependent phosphorylation of ubiquitin at Ser65.

Kazlauskaite A, Kondapalli C, Gourlay R, Campbell DG, Ritorto MS, Hofmann K, Alessi DR, Knebel A, Trost M, Muqit MM.

Biochem J. 2014 May 15;460(1):127-39. doi: 10.1042/BJ20140334.

10.

Phosphorylation of Parkin at Serine65 is essential for activation: elaboration of a Miro1 substrate-based assay of Parkin E3 ligase activity.

Kazlauskaite A, Kelly V, Johnson C, Baillie C, Hastie CJ, Peggie M, Macartney T, Woodroof HI, Alessi DR, Pedrioli PG, Muqit MM.

Open Biol. 2014 Mar 19;4:130213. doi: 10.1098/rsob.130213.

11.

Cognitive and motor function in long-duration PARKIN-associated Parkinson disease.

Alcalay RN, Caccappolo E, Mejia-Santana H, Tang MX, Rosado L, Orbe Reilly M, Ruiz D, Louis ED, Comella CL, Nance MA, Bressman SB, Scott WK, Tanner CM, Mickel SF, Waters CH, Fahn S, Cote LJ, Frucht SJ, Ford B, Rezak M, Novak KE, Friedman JH, Pfeiffer RF, Marsh L, Hiner B, Payami H, Molho E, Factor SA, Nutt JG, Serrano C, Arroyo M, Ottman R, Pauciulo MW, Nichols WC, Clark LN, Marder KS.

JAMA Neurol. 2014 Jan;71(1):62-7. doi: 10.1001/jamaneurol.2013.4498.

12.

Identifying the genetic components underlying the pathophysiology of movement disorders.

Ezquerra M, Compta Y, Marti MJ.

Appl Clin Genet. 2011 Jun 23;4:81-92. doi: 10.2147/TACG.S7333. Print 2011.

13.

Genetic basis of Parkinson's disease: inheritance, penetrance, and expression.

Schulte C, Gasser T.

Appl Clin Genet. 2011 Jun 1;4:67-80. doi: 10.2147/TACG.S11639. Print 2011.

14.

Variability in clinical phenotypes of heterozygous and homozygous cases of Parkin-related Parkinson's disease.

Thompson AJ, Scholz SW, Singleton AB, Hardwick A, McFarland NR, Okun MS.

Int J Neurosci. 2013 Dec;123(12):847-9. doi: 10.3109/00207454.2013.810626. Epub 2013 Jul 9.

15.

Levodopa Responsiveness in Adult-onset Lower Limb Dystonia is Associated with the Development of Parkinson's Disease.

Chang FC, Josephs KA.

Tremor Other Hyperkinet Mov (N Y). 2013 Apr 18;3. pii: tre-03-150-3598-2. Print 2013.

16.

Parkin disease: a clinicopathologic entity?

Doherty KM, Silveira-Moriyama L, Parkkinen L, Healy DG, Farrell M, Mencacci NE, Ahmed Z, Brett FM, Hardy J, Quinn N, Counihan TJ, Lynch T, Fox ZV, Revesz T, Lees AJ, Holton JL.

JAMA Neurol. 2013 May;70(5):571-9. doi: 10.1001/jamaneurol.2013.172.

17.

Pathway-specific dopaminergic deficits in a mouse model of Angelman syndrome.

Riday TT, Dankoski EC, Krouse MC, Fish EW, Walsh PL, Han JE, Hodge CW, Wightman RM, Philpot BD, Malanga CJ.

J Clin Invest. 2012 Dec;122(12):4544-54. doi: 10.1172/JCI61888. Epub 2012 Nov 12.

18.

Understanding and prevention of "therapy-" induced dyskinesias.

Aviles-Olmos I, Kefalopoulou Z, Foltynie T.

Parkinsons Dis. 2012;2012:640815. doi: 10.1155/2012/640815. Epub 2012 May 23.

19.

Clinical approach to Parkinson's disease: features, diagnosis, and principles of management.

Massano J, Bhatia KP.

Cold Spring Harb Perspect Med. 2012 Jun;2(6):a008870. doi: 10.1101/cshperspect.a008870.

20.

Cognitive impairment and dementia in Parkinson's disease: clinical features, diagnosis, and management.

Meireles J, Massano J.

Front Neurol. 2012 May 25;3:88. doi: 10.3389/fneur.2012.00088. eCollection 2012.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk